---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-071048"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2024-06-13T23:59:59+00:00"
generated_at: "2026-06-01T04:37:37.894694+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Voyager Therapeutics appoints Nathan Jorgensen as CFO effective July 8, 2024

## Summary
- Jorgensen, 47, previously CFO of Vor Biopharma; will report to CEO Alfred Sandrock.
- Annual base salary of $480,000; target annual bonus of 40% of base salary.
- Inducement equity grants: option to purchase 200,000 shares (4-year vest) and RSU for 80,000 shares (3-year vest).
- Severance: 12 months base salary plus pro-rata bonus and COBRA on termination without cause or for good reason within 12 months of a sale event.
- Employment at-will; standard non-compete and non-solicitation provisions.

## SEC filing metadata
- accession: 0001104659-24-071048
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2024-06-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000110465924071048/0001104659-24-071048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000110465924071048/tm2417027d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-071048
- JSON: https://secwatch.observer/filing/0001104659-24-071048.json
- Plain text: https://secwatch.observer/filing/0001104659-24-071048.txt

## Key facts
- Executive change
  Nathan Jorgensen was appointed as Chief Financial Officer at Voyager Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On June 11, 2024, Voyager Therapeutics, Inc. (the “Company”) and Nathan Jorgensen entered into an employment agreement (the “Jorgensen Agreement”), pursuant to which Dr. Jorgensen agreed to serve as the Chief Financial Officer of the Company, with his employment to commence no later than July 8, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1640266/000110465924071048/0001104659-24-071048-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.